Fig. 5: Correlations between HX103-based FACS and EGFR-activating mutations in surgically resected samples from NSCLC patients. | Nature Communications

Fig. 5: Correlations between HX103-based FACS and EGFR-activating mutations in surgically resected samples from NSCLC patients.

From: A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Fig. 5

a Bar chart showing the percentage of HX103(+), EGFR(+), and EGFR(+)HX103(+) in 23 surgical tumor samples (Table 1 and Supplementary Table 4). b Discriminating EGFR-activating mutations of 23 surgical tumor samples from NSCLC patients by the percent of EGFR(+)HX103(+). Confusion matrix analysis was performed by using the threshold of 30.1%, which is determined from ROC curves in Supplementary Fig. 23. It should be noted that the tumor tissues were from the patients diagnosed without any treatment. c Two-dimensional scatterplots of droplet digital PCR assay showing EGFR 19del positive for tumor sample #9-T. Source data are provided as a Source Data file.

Back to article page